CONSORT-EHEALTH (V 1.6.1) -Submission/Publication Form

The CONSORT-EHEALTH checklist is intended for authors of randomized trials evaluating web-based and Internet-based applications/interventions, including mobile interventions, electronic games (incl multiplayer games), social media, certain telehealth applications, and other interactive and/or networked electronic applications. Some of the items (e.g. all subitems under item 5 - description of the intervention) may also be applicable for other study designs.

The goal of the CONSORT EHEALTH checklist and guideline is to be a) a guide for reporting for authors of RCTs, b) to form a basis for appraisal of an ehealth trial (in terms of validity)

CONSORT-EHEALTH items/subitems are MANDATORY reporting items for studies published in the Journal of Medical Internet Research and other journals / scientific societies endorsing the checklist.

Items numbered 1., 2., 3., 4a., 4b etc are original CONSORT or CONSORT-NPT (nonpharmacologic treatment) items. Items with Roman numerals (i., ii, iii, iv etc.) are CONSORT-EHEALTH extensions/clarifications.

As the CONSORT-EHEALTH checklist is still considered in a formative stage, we would ask that you also RATE ON A SCALE OF 1-5 how important/useful you feel each item is FOR THE PURPOSE OF THE CHECKLIST and reporting guideline (optional).

Mandatory reporting items are marked with a red *.

In the textboxes, either copy & paste the relevant sections from your manuscript into this form - please include any quotes from your manuscript in QUOTATION MARKS, or answer directly by providing additional information not in the manuscript, or elaborating on why the item was not relevant for this study.

YOUR ANSWERS WILL BE PUBLISHED AS A SUPPLEMENTARY FILE TO YOUR PUBLICATION IN JMIR AND ARE CONSIDERED PART OF YOUR PUBLICATION (IF ACCEPTED). Please fill in these questions diligently. Information will not be copyedited, so please use proper spelling and grammar, use correct capitalization, and avoid abbreviations.

DO NOT FORGET TO SAVE AS PDF _AND_ CLICK THE SUBMIT BUTTON SO YOUR ANSWERS ARE IN OUR DATABASE !!!

Citation Suggestion (if you append the pdf as Appendix we suggest to cite this paper in the caption):

Eysenbach G, CONSORT-EHEALTH Group

CONSORT-EHEALTH: Improving and Standardizing Evaluation Reports of Web-based and

Mobile Health Interventions J Med Internet Res 2011;13(4):e126 URL: <u>http://www.jmir.org/2011/4/e126/</u> doi: 10.2196/jmir.1923 PMID: 22209829

andrade.andreq@gmail.com (not shared) Switch accounts

Draft saved

*Required

Your name *

First Last

Andre Q Andrade

Primary Affiliation (short), City, Country *

University of Toronto, Toronto, Canada

University of South Australia, Adelaide, Austral

Your e-mail address * abc@gmail.com

andre.andrade@unisa.edu.au

Title of your manuscript * Provide the (draft) title of your manuscript.

Implementation and Evaluation of a Digitally Enabled Precision Public Health Intervention to Reduce Inappropriate Gabapentinoid Prescription: Cluster Randomized Controlled Trial

Name of your App/Software/Intervention *

If there is a short and a long/alternate name, write the short name first and add the long name in brackets.

Veterans' MATES

Evaluated Version (if any)

e.g. "V1", "Release 2017-03-01", "Version 2.0.27913"

Your answer

Language(s) *

What language is the intervention/app in? If multiple languages are available, separate by comma (e.g. "English, French")

English

URL of your Intervention Website or App

e.g. a direct link to the mobile app on app in appstore (itunes, Google Play), or URL of the website. If the intervention is a DVD or hardware, you can also link to an Amazon page.

www.veteransmates.net.au

URL of an image/screenshot (optional)

Your answer

Accessibility * Can an enduser access the intervention presently? access is free and open access only for special usergroups, not open access is open to everyone, but requires payment/subscription/in-app purchases

) app/intervention no longer accessible

Other:

Primary Medical Indication/Disease/Condition *

e.g. "Stress", "Diabetes", or define the target group in brackets after the condition, e.g. "Autism (Parents of children with)", "Alzheimers (Informal Caregivers of)"

Pain (gabapentinoids user)

Primary Outcomes measured in trial *

comma-separated list of primary outcomes reported in the trial

change in average gabapentinoid prescription,

Secondary/other outcomes

Are there any other outcomes the intervention is expected to affect?

time to the first visit (face-to-face, telephone, or video) with the primary provider

Recommended "Dose" * What do the instructions for users say on how often the app should be used?
O Approximately Daily
O Approximately Weekly
O Approximately Monthly
O Approximately Yearly
O "as needed"
• Other: Single use intervention aimed at the primary provider, stored in the clir

Approx. Percentage of Users (starters) still using the app as recommended after 3 months *

	unknown /	not evalu	ated
--	-----------	-----------	------

- 0-10%
- 11-20%
- 21-30%
- 31-40%
- 41-50%
- 51-60%
- 61-70%
- 71%-80%
- 81-90%
- 91-100%
- Other:

Overall, was the app/intervention effective? *
O yes: all primary outcomes were significantly better in intervention group vs control
partly: SOME primary outcomes were significantly better in intervention group vs control
ono statistically significant difference between control and intervention
O potentially harmful: control was significantly better than intervention in one or more outcomes
inconclusive: more research is needed
O Other:

Article Preparation Status/Stage * At which stage in your article preparation are you currently (at the time you fill in this form)
O not submitted yet - in early draft status
onot submitted yet - in late draft status, just before submission
Submitted to a journal but not reviewed yet
Submitted to a journal and after receiving initial reviewer comments
submitted to a journal and accepted, but not published yet
O published
O Other:

Journal *

If you already know where you will submit this paper (or if it is already submitted), please provide the journal name (if it is not JMIR, provide the journal name under "other")

$\mathbf{)}$	not submitted ye	et / unclear	where I	will submit this
--------------	------------------	--------------	---------	------------------

- Journal of Medical Internet Research (JMIR)
- JMIR mHealth and UHealth



-) JMIR Mental Health
- JMIR Public Health
- JMIR Formative Research
- Other JMIR sister journal
- Other:

Is this a full powered effectiveness trial or a pilot/feasibility trial? *

Pilot/feasibility

Fully powered

Manuscript tracking number *

If this is a JMIR submission, please provide the manuscript tracking number under "other" (The ms tracking number can be found in the submission acknowledgement email, or when you login as author in JMIR. If the paper is already published in JMIR, then the ms tracking number is the four-digit number at the end of the DOI, to be found at the bottom of each published article in JMIR)

) no ms number (yet) / not (yet) submitted to / published in JMIR

) Other: 33873


TITLE AND ABSTRACT

1a) TITLE: Identification as a randomized trial in the title

1a) Does your paper address CONSORT item 1a? *
I.e does the title contain the phrase "Randomized Controlled Trial"? (if not, explain the reason under "other")
() yes
O Other:

1a-i) Identify the mode of delivery in the title

Identify the mode of delivery. Preferably use "web-based" and/or "mobile" and/or "electronic game" in the title. Avoid ambiguous terms like "online", "virtual", "interactive". Use "Internet-based" only if Intervention includes non-web-based Internet components (e.g. email), use "computer-based" or "electronic" only if offline products are used. Use "virtual" only in the context of "virtual reality" (3-D worlds). Use "online" only in the context of "online support groups". Complement or substitute product names with broader terms for the class of products (such as "mobile" or "smart phone" instead of "iphone"), especially if the application runs on different platforms.



Does your paper address subitem 1a-i? *

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study


"Digitally Enabled" (used secure digital message delivery, encoded as HL7 document)

1a-ii) Non-web-based components or important co-interventions in title							
Mention non-web-based components or important co-interventions in title, if any (e.g., "with telephone support").							
	1	2	3	4	5		
subitem not at all important	0	۲	0	0	0	essential	
					C	Clear selection	

Does your paper address subitem 1a-ii?

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Control group requires further explanation, contained in the Methods section



Does your paper address subitem 1a-iii? *

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Reduce Inappropriate Gabapentinoid Prescription

1b) ABSTRACT: Structured summary of trial design, methods, results, and

conclusions

NPT extension: Description of experimental treatment, comparator, care providers, centers, and blinding status.

1b-i) Key features/functionalities/components of the intervention and

comparator in the METHODS section of the ABSTRACT

Mention key features/functionalities/components of the intervention and comparator in the abstract. If possible, also mention theories and principles used for designing the site. Keep in mind the needs of systematic reviewers and indexers by including important synonyms. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
					C	Clear selection

Does your paper address subitem 1b-i? *

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"targeted education and patient-specific audit with feedback to Australian general practitioners"

1b-ii) Level of human involvement in the METHODS section of the ABSTRACT

Clarify the level of human involvement in the abstract, e.g., use phrases like "fully automated" vs. "therapist/nurse/care provider/physician-assisted" (mention number and expertise of providers involved, if any). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

	1	2	3	4	5	
subitem not at all important	۲	0	0	0	0	essential
					C	Clear selection


Does your paper address subitem 1b-ii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

audit and feedback do not require human involvement, described in the methods

1b-iii) Open vs. closed, web-based (self-assessment) vs. face-to-face assessments in the METHODS section of the ABSTRACT

Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic or a closed online user group (closed usergroup trial), and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment). Clearly say if outcomes were self-assessed through questionnaires (as common in web-based trials). Note: In traditional offline trials, an open trial (open-label trial) is a type of clinical trial in which both the researchers and participants know which treatment is being administered. To avoid confusion, use "blinded" or "unblinded" to indicated the level of blinding instead of "open", as "open" in web-based trials usually refers to "open access" (i.e. participants can self-enrol). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)



Does your paper address subitem 1b-iii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Veterans using gabapentinoids were targeted, their GPs were enrolled

1b-iv) RESULTS section in abstract must contain use data

Report number of participants enrolled/assessed in each group, the use/uptake of the intervention (e.g., attrition/adherence metrics, use over time, number of logins etc.), in addition to primary/secondary outcomes. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

	1	2	3	4	5	
subitem not at all important	۲	0	0	0	0	essential
					C	Clear selection

Does your paper address subitem 1b-iv?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Engagement metrics are not relevant for this kind of intervention

1b-v) CONCLUSIONS/DISCUSSION in abstract for negative trials

Conclusions/Discussions in abstract for negative trials: Discuss the primary outcome - if the trial is negative (primary outcome not changed), and the intervention was not used, discuss whether negative results are attributable to lack of uptake and discuss reasons. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
					C	Clear selection

Does your paper address subitem 1b-v?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"We found no difference between digital and postal mode of delivery in reduction of gabapentinoid prescriptions at 12 months"

INTRODUCTION

2a) In INTRODUCTION: Scientific background and explanation of rationale

2a-i) Problem and the type of system/solution

Describe the problem and the type of system/solution that is object of the study: intended as stand-alone intervention vs. incorporated in broader health care program? Intended for a particular patient population? Goals of the intervention, e.g., being more cost-effective to other interventions, replace or complement other solutions? (Note: Details about the intervention are provided in "Methods" under 5) $1 \quad 2 \quad 3 \quad 4 \quad 5$

		-	Ū.	-	Ū.	
subitem not at all important	0	0	0	0	٢	essential
					(Clear selection


Does your paper address subitem 2a-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Described audit and feedback as digitally enabled tools for professional behaviour change

2a-ii) Scientific background, rationale: What is known about the (type of) system

Scientific background, rationale: What is known about the (type of) system that is the object of the study (be sure to discuss the use of similar systems for other conditions/diagnoses, if appropiate), motivation for the study, i.e. what are the reasons for and what is the context for this specific study, from which stakeholder viewpoint is the study performed, potential impact of findings [2]. Briefly justify the choice of the comparator.



Does your paper address subitem 2a-ii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Despite the potential advantages of electronic delivery, there is a theoretical and evidence gap regarding the influence of changing the mode of delivery on the efficacy of behavior change intervention"

2b) In INTRODUCTION: Specific objectives or hypotheses

Does your paper address CONSORT subitem 2b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"To test the efficacy of the digital intervention, we (the authors) performed a cluster randomized trial of an intervention aimed at reducing inappropriate prescription of gabapentinoids by primary care providers."

METHODS

3a) Description of trial design (such as parallel, factorial) including allocation ratio

Does your paper address CONSORT subitem 3a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"To test the influence of mode of delivery on the effectiveness of audit and feedback interventions, we performed a parallel, cluster randomized trial of a computer-delivered intervention to reduce inappropriate gabapentinoid prescription. The trial was designed to compare the post-delivered intervention (usual intervention as concurrent control) with the computer-delivered intervention. Since the intervention targets GPs who may have multiple veteran patients, we adopted a cluster design whereby a GP received information for all of their patients in the intervention by the same mode."

3b) Important changes to methods after trial commencement (such as eligibility criteria), with reasons

Does your paper address CONSORT subitem 3b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This item is not applicable for this study.

3b-i) Bug fixes, Downtimes, Content Changes

Bug fixes, Downtimes, Content Changes: ehealth systems are often dynamic systems. A description of changes to methods therefore also includes important changes made on the intervention or comparator during the trial (e.g., major bug fixes or changes in the functionality or content) (5-iii) and other "unexpected events" that may have influenced study design such as staff changes, system failures/downtimes, etc. [2].

	1	2	3	4	5	
subitem not at all important	۲	0	0	0	0	essential
					C	Clear selection

Does your paper address subitem 3b-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This item is not applicable for this study.

4a) Eligibility criteria for participants


Does your paper address CONSORT subitem 4a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"To be eligible for participation, both veterans and their primary GP had to be eligible for the digital intervention. Eligible veterans comprised active DVA clients that had 2 or more gabapentinoid (either pregabalin or gabapentin) prescriptions in a 4-month period (October 2019 to January 2020). Veterans were also required to be resident in Australia, living in the community setting (ie, not residing in aged care or other long-term care facilities), and to not have previously requested exclusion from Veterans'MATES interventions for any reason. GPs were eligible if they were identified as the primary GP of one or more Australian veterans, and at least one of the veterans was eligible for the intervention. Participant GPs were excluded if they did not have installed capacity to receive secure electronic messages from our partner message provider (HealthLink Group Limited) or if they had previously requested exclusion from Veterans'MATES interventions for any reason."

4a-i) Computer / Internet literacy

Computer / Internet literacy is often an implicit "de facto" eligibility criterion - this should be explicitly clarified.




Does your paper address subitem 4a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Participant GPs were excluded if they did not have installed capacity to receive secure electronic messages from our partner message provider (HealthLink Group Limited) "

4a-ii) Open vs. closed, web-based vs. face-to-face assessments:

Open vs. closed, web-based vs. face-to-face assessments: Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic, and clarify if this was a purely webbased trial, or there were face-to-face components (as part of the intervention or for assessment), i.e., to what degree got the study team to know the participant. In online-only trials, clarify if participants were quasi-anonymous and whether having multiple identities was possible or whether technical or logistical measures (e.g., cookies, email confirmation, phone calls) were used to detect/prevent these.



Does your paper address subitem 4a-ii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The trial was conducted across all Australian states and territories. We determined patient eligibility by querying the DVA claims database."

4a-iii) Information giving during recruitment

Information given during recruitment. Specify how participants were briefed for recruitment and in the informed consent procedures (e.g., publish the informed consent documentation as appendix, see also item X26), as this information may have an effect on user self-selection, user expectation and may also bias results.

	1	2	3	4	5	
subitem not at all important	۲	0	0	0	0	essential
					C	Clear selection

Does your paper address subitem 4a-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study


This item is not applicable for this study (general practitioners were already enrolled in the Veterans' MATES program since 2004).

4b) Settings and locations where the data were collected

Does your paper address CONSORT subitem 4b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The trial was conducted across all Australian states and territories. We determined patient eligibility by querying the DVA claims database. Outcome data including service provision and medicine dispensing were collected from the DVA claims database."



Does your paper address subitem 4b-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This item is not applicable to this study.

5) The interventions for each group with sufficient details to allow replication, including how and when they were actually administered

5-i) Mention names, credential, affiliations of the developers, sponsors, and owners
Mention names, credential, affiliations of the developers, sponsors, and owners [6] (if authors/evaluators are owners or developer of the software, this needs to be declared in a "Conflict of interest" section or mentioned elsewhere in the manuscript).
1 2 3 4 5
subitem not at all important O O O O O O essential

Does your paper address subitem 5-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The proposed solution is an adaptation of the 3 steps used by Veterans' MATES interventions, suited for a digital medium"

5-ii) Describe the history/development process							
Describe the history/development process of the application and previous formative evaluations (e.g., focus groups, usability testing), as these will have an impact on adoption/use rates and help with interpreting results.							
	1	2	3	4	5		
subitem not at all important	0	0	0	0	٢	essential	
						Clear selection	


Does your paper address subitem 5-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The most important implementation risk identified during the initial stakeholder meetings was that the intervention could be perceived as intrusive and disruptive to GP workflow. To mitigate this risk, the solution was trialed in 3 sequential small-scale pilots, taking place in April, July, and September 2019."

5-iii) Revisions and updating

Revisions and updating. Clearly mention the date and/or version number of the application/intervention (and comparator, if applicable) evaluated, or describe whether the intervention underwent major changes during the evaluation process, or whether the development and/or content was "frozen" during the trial. Describe dynamic components such as news feeds or changing content which may have an impact on the replicability of the intervention (for unexpected events see item 3b).



Does your paper address subitem 5-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This item is not applicable to this study.

5-iv) Quality assurance methods

Provide information on quality assurance methods to ensure accuracy and quality of information provided [1], if applicable.

	1	2	3	4	5	
subitem not at all important	۲	0	0	0	0	essential
					C	Clear selection

Does your paper address subitem 5-iv?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This item is not applicable to this study.

5-v) Ensure replicability by publishing the source code, and/or providing							
screenshots/screen-capture video, and/or providing flowcharts of the algorithms							
used							
Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video, and/or providing flowcharts of the algorithms used. Replicability (i.e., other researchers should in principle be able to replicate the study) is a hallmark of scientific reporting.							
	1	2	3	4	5		
subitem not at all important	0	0	0	۲	0	essential	
Clear selection							


Does your paper address subitem 5-v?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Since we could not deliver general educational documents to the health record, the audit and feedback document was enhanced to contain a link to the online educational material (see Figure 1). Additionally, the single letter containing multiple patients was segmented into one electronic document per patient. Finally, a color chart was added at the top of the electronic document to highlight different prescription patterns and help GPs prioritize patients when receiving multiple documents."

5-vi) Digital preservation

Digital preservation: Provide the URL of the application, but as the intervention is likely to change or disappear over the course of the years; also make sure the intervention is archived (Internet Archive, <u>webcitation.org</u>, and/or publishing the source code or screenshots/videos alongside the article). As pages behind login screens cannot be archived, consider creating demo pages which are accessible without login.




Does your paper address subitem 5-vi?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The material can be found on the Veterans' MATES web page"

5-vii) Access

Access: Describe how participants accessed the application, in what setting/context, if they had to pay (or were paid) or not, whether they had to be a member of specific group. If known, describe how participants obtained "access to the platform and Internet" [1]. To ensure access for editors/reviewers/readers, consider to provide a "backdoor" login account or demo mode for reviewers/readers to explore the application (also important for archiving purposes, see vi).




Does your paper address subitem 5-vii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"GPs in the intervention arm received the intervention exclusively in a digitally delivered format. It was sent via secure message infrastructure directly to the GP's clinic. Once received by the practice, it is reviewed by a practice manager of the GP and assigned to the appropriate patient. Once it is assigned, it can be accessed in the electronic health record alongside pathology reports and referral letters"

5-viii) Mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework

Describe mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework [6] used to design them (instructional strategy [1], behaviour change techniques, persuasive features, etc., see e.g., [7, 8] for terminology). This includes an in-depth description of the content (including where it is coming from and who developed it) [1]," whether [and how] it is tailored to individual circumstances and allows users to track their progress and receive feedback" [6]. This also includes a description of communication delivery channels and – if computer-mediated communication is a component – whether communication was synchronous or asynchronous [6]. It also includes information on presentation strategies [1], including page design principles, average amount of text on pages, presence of hyperlinks to other resources, etc. [1].



Does your paper address subitem 5-viii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The intervention is informed by social cognitive theory [12], the transtheoretical model [13], and the health promotion model PRECEDE-PROCEED [14]." "The trial was designed to compare the postdelivered intervention (usual intervention as concurrent control) with the computer-delivered intervention. Since the intervention targets GPs who may have multiple veteran patients, we adopted a cluster design whereby a GP received information for all of their patients in the intervention by the same mode."

5-ix) Describe use parameters

Describe use parameters (e.g., intended "doses" and optimal timing for use). Clarify what instructions or recommendations were given to the user, e.g., regarding timing, frequency, heaviness of use, if any, or was the intervention used ad libitum.



Does your paper address subitem 5-ix?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This item is not applicable to this study.

5-x) Clarify the level of human involvement

Clarify the level of human involvement (care providers or health professionals, also technical assistance) in the e-intervention or as co-intervention (detail number and expertise of professionals involved, if any, as well as "type of assistance offered, the timing and frequency of the support, how it is initiated, and the medium by which the assistance is delivered". It may be necessary to distinguish between the level of human involvement required for the trial, and the level of human involvement required for a routine application outside of a RCT setting (discuss under item 21 – generalizability).



Does your paper address subitem 5-x?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

5-xi) Report any prompts/reminders used

Report any prompts/reminders used: Clarify if there were prompts (letters, emails, phone calls, SMS) to use the application, what triggered them, frequency etc. It may be necessary to distinguish between the level of prompts/reminders required for the trial, and the level of prompts/reminders for a routine application outside of a RCT setting (discuss under item 21 – generalizability).

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

Does your paper address subitem 5-xi? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"GPs in the intervention arm received the intervention exclusively in a digitally delivered format. It was sent via secure message infrastructure directly to the GP's clinic. Once received by the practice, it is reviewed by a practice manager of the GP and assigned to the appropriate patient. Once it is assigned, it can be accessed in the electronic health record alongside pathology reports and referral letters."

5-xii) Describe any co-interventions (incl. training/support)

Describe any co-interventions (incl. training/support): Clearly state any interventions that are provided in addition to the targeted eHealth intervention, as ehealth intervention may not be designed as stand-alone intervention. This includes training sessions and support [1]. It may be necessary to distinguish between the level of training required for the trial, and the level of training for a routine application outside of a RCT setting (discuss under item 21 – generalizability.

	1	2	3	4	5	
subitem not at all important	۲	0	0	0	0	essential
					C	Clear selection

Does your paper address subitem 5-xii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No co-interventions were included in this study

6a) Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed

Does your paper address CONSORT subitem 6a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study


"The total mass amount was determined according to all claimed prescriptions of gabapentin and pregabalin in the 3 months prior to the intervention (January 3, 2020, to April 2, 2020) and in the 6 months (July 3, 2020, to October 2, 2020) and 12 months (January 3, 2021, to April 2, 2021) following the intervention."


6a-i) Online questionnaires: describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were									
designed/deployed									
If outcomes were obtained through online questionnaires, describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed [9].									
	1	2	3	4	5				
subitem not at all important	۲	0	0	0	0	essential			
Clear selection									

Does your paper address subitem 6a-i? Copy and paste relevant sections from manuscript text No online questionnaires were used.

6a-ii) Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored

Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored (logins, logfile analysis, etc.). Use/adoption metrics are important process outcomes that should be reported in any ehealth trial.





Does your paper address subitem 6a-iii?

Copy and paste relevant sections from manuscript text

"For the first pilot, a convenience sample of 75 GPs were sent an email invitation to participate (opt-in), and 5 GPs agreed to be included. For the second pilot, we selected a convenience sample of 20 GPs who could opt out of the pilot. For the third pilot, 189 messages were sent to GPs who had not participated previously. We received 6 survey responses, and all responders evaluated the usability as good (easy to read, correct information) and were either likely or very likely to continue to subscribe to future interventions. We received a single letter advising a patient had recently switched medical providers. Given the lack of negative feedback and positive survey responses, the project leadership considered the pilot successful and the intervention feasible, and approved the randomized controlled trial.

6b) Any changes to trial outcomes after the trial commenced, with reasons

Does your paper address CONSORT subitem 6b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No changes were made after commencement

7a) How sample size was determined

NPT: When applicable, details of whether and how the clustering by care provides or centers was addressed

7a-i) Describe whether and how expected attrition was taken into account when calculating the sample size Describe whether and how expected attrition was taken into account when calculating the sample size.						
	1	2	3	4	5	
subitem not at all important	۲	0	0	0	0	essential
					(Clear selection

Does your paper address subitem 7a-i?

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Attrition is not relevant for this study (single use)

7b) When applicable, explanation of any interim analyses and stopping guidelines

Does your paper address CONSORT subitem 7b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This item is not applicable for this study

8a) Method used to generate the random allocation sequence

NPT: When applicable, how care providers were allocated to each trial group

Does your paper address CONSORT subitem 8a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"GPs were randomized 1:1 to intervention or usual care. Randomization was block stratified by number of veterans under care. Randomization numbers for each GP were computer generated by a statistician who was not involved in enrolment. Due to the highly automated nature of the intervention and data collection (claims data), no further masking procedures were performed.

8b) Type of randomisation; details of any restriction (such as blocking and block size)

Does your paper address CONSORT subitem 8b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"GPs were randomized 1:1 to intervention or usual care. Randomization was block stratified by number of veterans under care. Randomization numbers for each GP were computer generated by a statistician who was not involved in enrolment. Due to the highly automated nature of the intervention and data collection (claims data), no further masking procedures were performed.

9) Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned

Does your paper address CONSORT subitem 9?*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"GPs were randomized 1:1 to intervention or usual care. Randomization was block stratified by number of veterans under care. Randomization numbers for each GP were computer generated by a statistician who was not involved in enrolment. Due to the highly automated nature of the intervention and data collection (claims data), no further masking procedures were performed.

10) Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions

Does your paper address CONSORT subitem 10? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Randomization numbers for each GP were computer generated by a statistician who was not involved in enrolment."


11a) If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how NPT: Whether or not administering co-interventions were blinded to group assignment

11a-i) Specify who was blinded, and who wasn't						
Specify who was blinded, and who wasn't. Usually, in web-based trials it is not possible to blind the participants [1, 3] (this should be clearly acknowledged), but it may be possible to blind outcome assessors, those doing data analysis or those administering co-interventions (if any).						
	1	2	3	4	5	
subitem not at all important	0	0	0	۲	0	essential
					C	Clear selection

Does your paper address subitem 11a-i?*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Randomization numbers for each GP were computer generated by a statistician who was not involved in enrolment."



Does your paper address subitem 11a-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"GPs in the intervention arm received the intervention exclusively in a digitally delivered format. It was sent via secure message infrastructure directly to the GP's clinic. Once received by the practice, it is reviewed by a practice manager of the GP and assigned to the appropriate patient. Once it is assigned, it can be accessed in the electronic health record alongside pathology reports and referral letters.

GPs in the usual care arm received the intervention by postal service. This delivery contains both the audit and feedback documents (for all selected veteran patients) and the educational materials (including a copy of the material targeted at veterans)"

11b) If relevant, description of the similarity of interventions

(this item is usually not relevant for ehealth trials as it refers to similarity of a placebo or sham intervention to a active medication/intervention)

Does your paper address CONSORT subitem 11b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Both sets of materials contained the same theoretical content and personal information. Due to feedback from users, the digitally delivered intervention was slightly modified to user workflow. Since we could not deliver general educational documents to the health record, the audit and feedback document was enhanced to contain a link to the online educational material (see Figure 1). Additionally, the single letter containing multiple patients was segmented into one electronic document per patient. Finally, a color chart was added at the top of the electronic document to highlight different prescription patterns and help GPs prioritize patients when receiving multiple documents."

12a) Statistical methods used to compare groups for primary and secondary

outcomes

NPT: When applicable, details of whether and how the clustering by care providers or centers was addressed


Does your paper address CONSORT subitem 12a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"We analyzed data from services and medicines claims for all enrolled patients who were alive at 12 months postintervention. To account for the cluster design, we analyzed the primary outcome using a linear mixed-effects model [28], with the GP as the grouping variable. The effect of mode of delivery on patients' likelihood of visiting a psychologist was tested by logistic regression, also using GP as the grouping variable"

12a-i) Imputation techniques to deal with attrition / missing values

Imputation techniques to deal with attrition / missing values: Not all participants will use the intervention/comparator as intended and attrition is typically high in ehealth trials. Specify how participants who did not use the application or dropped out from the trial were treated in the statistical analysis (a complete case analysis is strongly discouraged, and simple imputation techniques such as LOCF may also be problematic [4]).



Does your paper address subitem 12a-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This item is not relevant for this study

12b) Methods for additional analyses, such as subgroup analyses and adjusted analyses

Does your paper address CONSORT subitem 12b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

. The time to first GP visit was analyzed by survival analysis. Patients were considered to have the "event" if they had an appointment with the targeted GP. Events were right censored at 3 months (92 days). The relative effect of digital mode versus postal mode was evaluated by a Cox proportional hazards model, with the GP as cluster variable. Secondary analysis was performed by univariate linear mixed-effects model, with the GP as grouping variable

X26) REB/IRB Approval and Ethical Considerations [recommended as subheading under "Methods"] (not a CONSORT item)

X26-i) Comment on ethics co	ommitte	ee appro	oval			
	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
					C	Clear selection

Does your paper address subitem X26-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"An ethics protocol for the study was approved by the University of South Australia Human Research Ethics Committee (ethics protocol P203/04) and the Australian Government Department of Defence and Veterans' Affairs Human Research Ethics Committee (E016/007)

x26-ii) Outline informed consent procedures

Outline informed consent procedures e.g., if consent was obtained offline or online (how? Checkbox, etc.?), and what information was provided (see 4a-ii). See [6] for some items to be included in informed consent documents.



Does your paper address subitem X26-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This trial is a modification of a previous existing intervention running continuously since 2004 (4 modules each year), so there was no additional enrolment for this particular trial.

X26-iii) Safety and security procedures Safety and security procedures, incl. privacy considerations, and any steps taken to reduce the likelihood or detection of harm (e.g., education and training, availability of a hotline) 1 2 3 4 5 subitem not at all important essential **Clear selection**

Does your paper address subitem X26-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This item is not relevant for this study

RESULTS

13a) For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary

outcome

NPT: The number of care providers or centers performing the intervention in each group and the number of patients treated by each care provider in each center

Does your paper address CONSORT subitem 13a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"A total of 3271 veterans were considered eligible for the intervention, and 2552 GPs were identified as their main care providers (Figure 2). After randomization, the intervention was successfully delivered in March/April 2020. The postal intervention was sent to GPs on March 19, 2020. The computer-delivered intervention was delivered in three waves (on March 23, March 25, and April 2, 2020)."

13b) For each group, losses and exclusions after randomisation, together with reasons

Does your paper address CONSORT subitem 13b? (NOTE: Preferably, this is shown in a CONSORT flow diagram) *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Figure 2. CONSORT (Consolidated Standards of Reporting Trials) flowchart. GP: general practitioner"

13b-i) Attrition diagram Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in or using the intervention/comparator in each group plotted over time, similar to a survival curve) or other figures or tables demonstrating usage/dose/engagement. 1 2 3 5 4

subitem not at all important

Clear selection

essential

Does your paper address subitem 13b-i?

Copy and paste relevant sections from the manuscript or cite the figure number if applicable (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Attrition is not relevant for this study (single use).

14a) Dates defining the periods of recruitment and follow-up

Does your paper address CONSORT subitem 14a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The total mass amount was determined according to all claimed prescriptions of gabapentin and pregabalin in the 3 months prior to the intervention (January 3, 2020, to April 2, 2020) and in the 6 months (July 3, 2020, to October 2, 2020) and 12 months (January 3, 2021, to April 2, 2021) following the intervention"

14a-i) Indicate if critical "secular events" fell into the study period							
Indicate if critical "secular events" fell into the study period, e.g., significant changes in Internet resources available or "changes in computer hardware or Internet delivery resources"							
	1	2	3	4	5		
subitem not at all important	0	0	0	0	۲	essential	
					C	Clear selection	

Does your paper address subitem 14a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The timing of this study is an important limitation of this study, as intervention delivery coincided with the initial restrictions implemented in Australia in response to the COVID-19 pandemic in March 2020. The week of the intervention, several policies to restrict gatherings and reduce risk of contagion were enacted [33], which influenced some of the metrics used in this study. Medicine dispensing was likely affected, with stockpiling occurring and a temporary lack of access. Additionally, many clinics were closed to avoid waiting room risks, and appointments via telehealth were funded by the Department of Health. This may have influenced intervention effectiveness, as the opportunity to adjust therapy was reduced; however, it is unlikely to have affected the assessment of mode of delivery as both arms of the trial would have been equally affected by the COVID-19 restrictions. Postal mail services were fully maintained during restrictions."

14b) Why the trial ended or was stopped (early)

Does your paper address CONSORT subitem 14b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The trial ended as initially predicted

15) A table showing baseline demographic and clinical characteristics for each group

NPT: When applicable, a description of care providers (case volume, qualification, expertise, etc.) and centers (volume) in each group

Does your paper address CONSORT subitem 15? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study							
"Table 2. Clinical and demographic data at baseline."							
15-i) Report demographics a In ehealth trials it is particularly impo such as age, education, gender, socia participants, if known.	rtant to re	eport demo	ographics	associate	d with digit		
	1	2	3	4	5		
subitem not at all important	۲	0	0	0	0	essential	
					C	Clear selection	

Does your paper address subitem 15-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"We excluded all practitioners not found in the partner's (Healthlink Group Limited) provider directory, as they would be unable to receive secure electronic messages. "

16) For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups

16-i) Report multiple "denominators" and provide definitions

Report multiple "denominators" and provide definitions: Report N's (and effect sizes) "across a range of study participation [and use] thresholds" [1], e.g., N exposed, N consented, N used more than x times, N used more than y weeks, N participants "used" the intervention/comparator at specific pre-defined time points of interest (in absolute and relative numbers per group). Always clearly define "use" of the intervention.

	1	2	3	4	5	
subitem not at all important	۲	0	0	0	0	essential
					C	Clear selection

Does your paper address subitem 16-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not relevant for this study.

16-ii) Primary analysis should be intent-to-treat

Primary analysis should be intent-to-treat, secondary analyses could include comparing only "users", with the appropriate caveats that this is no longer a randomized sample (see 18-i).

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
					(Clear selection

Does your paper address subitem 16-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Engagement was not measured (single use), and all participants were considered in the analysis

17a) For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)

Does your paper address CONSORT subitem 17a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"By the end of the study, both intervention groups had a significant reduction in gabapentinoid dispensing, as measured by the change in average daily DDD from baseline to 12 months (digital: mean reduction of 0.058, SD 0.38, or 11.2%, P=.004; postal: mean reduction of 0.058, SD 0.37, or 11.2%, P=.001). We found no difference between digital and postal mode of delivery in reduction of gabapentinoid volume at 6 or 12 months (Table 3)"

17a-i) Presentation of process outcomes such as metrics of use and intensity of use In addition to primary/secondary (clinical) outcomes, the presentation of process outcomes such as metrics of use and intensity of use (dose, exposure) and their operational definitions is critical. This does not only refer to metrics of attrition (13-b) (often a binary variable), but also to more continuous exposure metrics such as "average session length". These must be accompanied by a technical description how a metric like a "session" is defined (e.g., timeout after idle time) [1] (report under item 6a). 2 3 1 4 5 subitem not at all important essential **Clear selection**

Does your paper address subitem 17a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Process outcomes are not relevant for this study

17b) For binary outcomes, presentation of both absolute and relative effect sizes is recommended

Does your paper address CONSORT subitem 17b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Table 3. Primary and secondary outcomes, by intervention arm.

18) Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory

Does your paper address CONSORT subitem 18?*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Veterans were segmented according to dose and concurrent opioid use. Consistent with the results of the primary analysis, no differences were found between the digital and postal interventions in any subgroup analysis. Dose reduction was more pronounced in high-dose gabapentinoid users, and there was no observed reduction in the average dose of low-dose users in either arm"

18-i) Subgroup analysis of comparing only users

A subgroup analysis of comparing only users is not uncommon in ehealth trials, but if done, it must be stressed that this is a self-selected sample and no longer an unbiased sample from a randomized trial (see 16-iii).

	1	2	3	4	5	
subitem not at all important	0	0	۲	0	0	essential
					C	Clear selection

Does your paper address subitem 18-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Veterans were segmented according to dose and concurrent opioid use. Consistent with the results of the primary analysis, no differences were found between the digital and postal interventions in any subgroup analysis. Dose reduction was more pronounced in high-dose gabapentinoid users, and there was no observed reduction in the average dose of low-dose users in either arm"

19) All important harms or unintended effects in each group

(for specific guidance see CONSORT for harms)

Does your paper address CONSORT subitem 19?*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable for this study.

19-i) Include privacy breaches, technical problems

Include privacy breaches, technical problems. This does not only include physical "harm" to participants, but also incidents such as perceived or real privacy breaches [1], technical problems, and other unexpected/unintended incidents. "Unintended effects" also includes unintended positive effects [2].



Does your paper address subitem 19-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No privacy breaches were detected.

19-ii) Include qualitative feedback from participants or observations from

staff/researchers

Include qualitative feedback from participants or observations from staff/researchers, if available, on strengths and shortcomings of the application, especially if they point to unintended/unexpected effects or uses. This includes (if available) reasons for why people did or did not use the application as intended by the developers.

	1	2	3	4	5	
subitem not at all important	0	۲	0	0	0	essential
					C	Clear selection

Does your paper address subitem 19-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"We received 6 survey responses, and all responders evaluated the usability as good (easy to read, correct information) and were either likely or very likely to continue to subscribe to future interventions. We received a single letter advising a patient had recently switched medical providers."

DISCUSSION

22) Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence

NPT: In addition, take into account the choice of the comparator, lack of or partial blinding, and unequal expertise of care providers or centers in each group

22-i) Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use)						
Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use).						
	1	2	3	4	5	
subitem not at all important	0	0	0	٢	0	essential
Clear selection						

Does your paper address subitem 22-i?*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"In this study, we present the successful migration of a paper-based national behavior change intervention into a digital intervention. After a careful scaling of the intervention, ample communication, and stakeholder support, we were able to perform a large-scale randomized controlled trial covering all Australian states. The trial showed that both paper and digital versions of an intervention composed of education and audit and feedback was effective in reducing gabapentinoid prescriptions for an Australian population. Additionally, it showed that the digital intervention is equivalent to paper in changing prescription patterns."



Does your paper address subitem 22-ii?


Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"This study also provides a foundation for further research aimed at improving the effectiveness of audit and feedback in public health digital interventions. The effect size of conventional and digital audit and feedback interventions is usually small [1,7], and a clear methodology to improve effect remains an open question. Effect may be influenced by factors related to the recipient (eg, GP), behavior, or content and delivery of the intervention [34]."

20) Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses

20-i) Typical limitations in ehealth trials

Typical limitations in ehealth trials: Participants in ehealth trials are rarely blinded. Ehealth trials often look at a multiplicity of outcomes, increasing risk for a Type I error. Discuss biases due to non-use of the intervention/usability issues, biases through informed consent procedures, unexpected events.



Does your paper address subitem 20-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study


"The timing of this study is an important limitation of this study, as intervention delivery coincided with the initial restrictions implemented in Australia in response to the COVID-19 pandemic in March 2020. The week of the intervention, several policies to restrict gatherings and reduce risk of contagion were enacted [33], which influenced some of the metrics used in this study. Medicine dispensing was likely affected, with stockpiling occurring and a temporary lack of access. Additionally, many clinics were closed to avoid waiting room risks, and appointments via telehealth were funded by the Department of Health. This may have influenced intervention effectiveness, as the opportunity to adjust therapy was reduced; however, it is unlikely to have affected the assessment of mode of delivery as both arms of the trial would have been equally affected by the COVID-19 restrictions. Postal mail services were fully maintained during restrictions"

21) Generalisability (external validity, applicability) of the trial findings

NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial

21-i) Generalizability to other populations

Generalizability to other populations: In particular, discuss generalizability to a general Internet population, outside of a RCT setting, and general patient population, including applicability of the study results for other organizations




Does your paper address subitem 21-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Digital delivery changes how participants interact with and experience the intervention. Integration with the patient electronic health record reduces the effort required to create new patient requests, such as actively inviting patients to a follow-up appointment."

21-ii) Discuss if there were elements in the RCT that would be different in a routine application setting

Discuss if there were elements in the RCT that would be different in a routine application setting (e.g., prompts/reminders, more human involvement, training sessions or other co-interventions) and what impact the omission of these elements could have on use, adoption, or outcomes if the intervention is applied outside of a RCT setting.



Does your paper address subitem 21-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This RCT was part of a routine application setting.

OTHER INFORMATION

23) Registration number and name of trial registry

Does your paper address CONSORT subitem 23? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

To reduce the bias in analysis, all analytic procedures (for this and all other interventions) are prospectively defined and submitted to the Australian Government Department of Veterans' Affairs for evaluation and approval. However, there is no formal registration number and the plan is not made public available due to confidentiality reasons.

24) Where the full trial protocol can be accessed, if available

Does your paper address CONSORT subitem 24? *

Cite a Multimedia Appendix, other reference, or copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The full trial protocol is not publicly available.

25) Sources of funding and other support (such as supply of drugs), role of funders

Does your paper address CONSORT subitem 25? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This work was funded by the Australian Government Department of Veterans' Affairs (DVA) as part of the Veterans' Medicines Advice and Therapeutics Education Services (Veterans'MATES) program.

X27) Conflicts of Interest (not a CONSORT item)

X27-i) State the relation of the in addition to the usual declaration of study team towards the system being identical with the developers/sponso	f interests g evaluate	s (financia ed, i.e., stat	or otherw e if the au	vise), also	state the r	elation of the	
	1	2	3	4	5		
subitem not at all important	0	0	0	۲	0	essential	
					C	Clear selection	
Does your paper address subitem X27-i? Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study Conflicts of Interest None declared.							
About the CONSORT EHEAI	_TH che	ecklist					
As a result of using this chec yes, major changes yes, minor changes no	klist, di	d you m	ake cha	nges in	your ma	nuscript? *	
What were the most importa checklist?	ant char	nges you	ı made a	as a resi	ılt of usi	ng this	
Your answer							

How much time did you spend on going through the checklist INCLUDING making changes in your manuscript * I spent 2 hours in total.
As a result of using this checklist, do you think your manuscript has improved? *
O no
• Other: As a professional behaviour change intervention, several items are no
Would you like to become involved in the CONSORT EHEALTH group? This would involve for example becoming involved in participating in a workshop and writing an "Explanation and Elaboration" document
⊖ yes
o no
O Other:
\sim
Clear selection
Any other comments or questions on CONSORT EHEALTH
Your answer

STOP - Save this form as PDF before you click submit

To generate a record that you filled in this form, we recommend to generate a PDF of this page (on a Mac, simply select "print" and then select "print as PDF") before you submit it.

When you submit your (revised) paper to JMIR, please upload the PDF as supplementary file.

Don't worry if some text in the textboxes is cut off, as we still have the complete information in our database. Thank you!

Final step: Click submit !

Click submit so we have your answers in our database!

Submit

Clear form

Never submit passwords through Google Forms.

This content is neither created nor endorsed by Google. Report Abuse - Terms of Service - Privacy Policy

